The new API aims to collect more accurate information by utilizing techniques designed to avoid altering patient behavior.
ObvioHealth announced the launch of an application programming interface (API), which it has designed specifically for clinical trials. The company describes itself as a virtual research organization and it says that the new API will reduce the burden on clinical trial participants while allowing for more data on adherence and efficacy to be captured.
According to the company, the API is better suited for collecting this data compared to traditional questionnaire methods. These questionnaires can potentially influence a patient’s behavior.
The API is available on ObvioHealth’s mobile app.
“Some trial partners will use separate apps to ask many of the same questions that are asked within the DTx— an annoyance for participants and an overly complicated trial design for sponsors. It’s important for sponsors to recognize these study design nuances that can have a dramatic impact on the integrity of study data and participant behavior,” said Ivan Jarry, ObvioHealth’s CEO, in a press release. “ObvioGo’s solution is uniquely positioned to overcome these DTx challenges and facilitate regulatory approvals.”
PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.